Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 12, 2025
Product Development
Promising early data for Tonghua Dongbao’s obesity program
BioCentury’s latest Clinical Report finds the obesity data came in a week when markets failed to reward readouts
BioCentury | Apr 3, 2024
Data Byte
Last minute flurry brings FDA’s first-quarter NME approvals to 10
Highlights include accelerated approval of first MASH therapy; plus Merck’s disease-modifying PAH therapy and Idorsia’s antihypertensive
BioCentury | Mar 14, 2024
Deals
AstraZeneca’s Amolyt takeout among largest ever for a French biotech
Deal for $800M up front adds hypoparathyroidism asset, now in Phase III, to AZ’s Alexion portfolio; shareholders could receive $250M milestone
BioCentury | Feb 24, 2024
Data Byte
EMA’s CHMP backs Biogen’s ALS drug and an IgAN therapy from CSL, Travere
The agency’s February decisions also include positive opinions for Tizveni, Voydeya and Zynyz, and label expansions for six therapies
BioCentury | Feb 8, 2023
Data Byte
Competition heats up in PNH with new Roche data
A dozen complement inhibitors behind Roche’s crovalimab also hope to challenge established therapies
BioCentury | Apr 9, 2022
Finance
April 8 Quick Takes: Kaleido winding down operations
Plus: BioCryst loses $1.2B in market cap after pivotal pause and the latest in CEPI investments and more
BioCentury | Dec 15, 2020
Deals
In $39B deal, AZ looks to grow rare disease business while Alexion’s investors gain value recognition
AZ’s presence in emerging markets could further expand Alexion’s complement franchise, despite looming competition
BioCentury | Jan 8, 2020
Clinical News
Apellis readies to compete with Soliris in PNH based on Phase III data
BioCentury | Oct 19, 2019
Finance
Achillion’s journey to $1 billion
Achillion's 21-year evolution from an antiviral play into a complement pathway company
BioCentury | Oct 17, 2019
Company News
Deal streak continues for Alexion as Achillion’s story hits $930M high note
Items per page:
1 - 10 of 44